Q2 2026 13F · SEC CIK 909661

Farallon Capital Management, L.l.c.

Hedge fundFiled 2026-08-14 for Q2 2026. Open the filing ↗ · All SEC filings ↗

Reported 13F value: $16.9B
Reported positions: 82
Top holdings a year, 3 yrs: +17.1%
Assets under management: $52.1B

Farallon Capital Management, L.l.c. is a hedge fund that reported 82 positions worth $16.9B in its Q2 2026 13F, filed 2026-08-14. Its largest holdings were Revolution Medicines Inc (RVMD, 15.0%), Electronic Arts Inc (EA, 9.6%), Bridgebio Pharma Inc (BBIO, 4.7%). A portfolio copying its top holdings returned 17.1% a year over the last 3 years, against 19.0% for the S&P 500.

Farallon Capital Management, L.l.c. holdings largest 50 of 82 positions.

Weights are shares of the filer's total reported 13F value, compared with Q1 2026. Share changes may reflect splits; weight changes also reflect price moves. A 13F shows long US-listed positions only, up to 135 days after the fact.

Farallon Capital Management, L.l.c. 13F holdings
Stock	% of 13F value	Q1 2026	Shares	Share change	Reported value
RVMDRevolution Medicines Inc	15.0%	8.7%	13,550,796	-0.4%	$2.5B
EAElectronic Arts Inc	9.6%	—	7,919,500	—	$1.6B
BBIOBridgebio Pharma Inc	4.7%	4.6%	10,743,063	+14.7%	$800.1M
PTGXProtagonist Therapeutics Inc	4.6%	4.4%	6,348,906	+0.0%	$778.2M
EXELExelixis Inc	4.3%	3.7%	13,468,010	+2.7%	$732.8M
LQDALiquidia Corporation	3.9%	2.1%	8,365,038	-3.4%	$666.9M
AMZNAmazon Com Inc	3.7%	5.8%	2,632,994	-37.6%	$627.5M
LNTHLantheus Hldgs Inc	3.7%	2.8%	5,583,479	+0.0%	$619.4M
NTRANatera Inc	3.6%	4.2%	2,218,366	-30.8%	$602.2M
UNHUnitedhealth Group Inc	3.1%	3.2%	1,270,532	-30.3%	$528.1M
TMOThermo Fisher Scientific Inc	3.1%	2.8%	1,049,185	+19.0%	$526.0M
ROIVRoivant Sciences Ltd	3.0%	1.8%	14,309,000	+47.9%	$506.4M
AONAon PLC	2.7%	5.3%	1,382,562	-45.0%	$458.6M
BSXBoston Scientific Corp	2.6%	3.1%	10,521,184	+40.8%	$449.0M
AVGOBroadcom Inc	2.6%	3.6%	1,151,800	-35.3%	$435.1M
MSFTMicrosoft Corp	2.5%	5.7%	1,112,863	-52.5%	$415.1M
TNGXTango Therapeutics Inc	2.3%	1.2%	12,277,000	+35.0%	$383.8M
KKRKkr & Co Inc	2.2%	2.8%	4,118,300	-11.8%	$378.0M
SNPSSynopsys Inc	2.2%	3.2%	829,600	-31.6%	$370.1M
BEAMBeam Therapeutics Inc	2.1%	1.6%	10,236,396	+1.0%	$351.3M
CRNXCrinetics Pharmaceuticals in	2.0%	2.0%	8,989,098	+7.8%	$336.4M
GRALGRAIL, Inc.	1.7%	1.1%	4,161,584	+27.9%	$284.1M
WABWabtec	1.4%	2.6%	894,503	-44.4%	$241.2M
IMVTImmunovant Inc	1.3%	0.3%	5,805,000	+275.5%	$223.7M
TWSTTwist Bioscience Corp	1.3%	0.4%	2,136,400	+49.6%	$219.8M
AGIOAgios Pharmaceuticals Inc	1.3%	1.3%	5,917,400	+4.1%	$219.6M
ARMKAramark	1.2%	1.6%	3,625,731	-40.9%	$206.3M
BIDUBaidu Inc	0.8%	0.3%	1,203,785	+171.3%	$137.6M
NVONovo-Nordisk A S	0.7%	—	2,619,000	—	$125.6M
ACHCAcadia Healthcare Company in	0.7%	0.3%	4,220,800	+143.0%	$124.6M
BTSGBrightspring Health Services I	0.7%	0.5%	1,732,800	+7.2%	$120.8M
AZNAstrazeneca PLC	0.6%	0.3%	574,000	+153.4%	$108.8M
JNJJohnson & Johnson	0.6%	0.2%	408,000	+175.7%	$103.6M
PBLSParabilis Medicines, Inc.	0.4%	—	2,368,200	—	$64.8M
NVSNovartis AG	0.3%	—	363,000	—	$56.9M
GHGuardant Health Inc	0.3%	—	322,200	—	$48.3M
AVTXAvalo Therapeutics Inc	0.3%	—	2,498,000	—	$46.2M
YYJOYY Inc	0.3%	0.2%	699,200	+20.9%	$46.1M
ASMBAssembly Biosciences Inc.	0.3%	0.2%	1,604,590	+30.7%	$44.1M
ENTAEnanta Pharmaceuticals Inc	0.2%	0.2%	2,418,202	-15.8%	$35.3M
MAZEMaze Therapeutics Inc	0.2%	—	1,107,814	—	$33.1M
MRKMerck & Co Inc	0.2%	0.3%	199,000	-44.9%	$25.6M
WRBYWarby Parker Inc	0.1%	—	828,000	—	$25.1M
PCSCPerceptive Capital Solution Cl A Ord	0.1%	—	2,250,000	—	$24.5M
KLRAKailera Therapeutics Inc	0.1%	—	1,100,000	—	$24.2M
RIORio Tinto PLC	0.1%	—	183,475	—	$17.4M
AXTAAxalta Coating Sys Ltd	0.1%	—	478,000	—	$16.4M
ABVXAbivax SA	0.1%	—	122,000	—	$16.3M
VNETVnet Group Inc	0.1%	—	1,992,000	—	$16.0M
NTESNetease Inc Sp ADR	0.1%	—	123,500	—	$15.8M

What Farallon Capital Management, L.l.c. bought and sold in Q2 2026, against Q1 2026.

New positions

Q1 2026's filing was too long to tell new positions apart.

Share counts compared with the Q1 2026 13F; a split also changes share counts. The latest filing lists more than 50 positions, so a position that left the top 50 may still be held.

How the holdings did against the S&P 500.

1 year: +30.6% /yr; S&P 500 +14.9%
3 years: +17.1% /yr; S&P 500 +19.0%
5 years: +9.3% /yr; S&P 500 +10.4%

A portfolio of the filer's 20 largest 13F positions, weighted by value, bought the trading day after each 13F was filed and held until the next one was: what copying this filer could have earned. 13Fs show long US-listed positions only, so this is an estimate of the stock picks, not the fund's reported returns.

Reported 13F value by quarter.

13F value by quarter
Quarter	13F value	Positions
Q2 2026	$16.9B	82
Q1 2026	$15.3B	167
Q4 2025	$17.3B	145
Q3 2025	$17.7B	139
Q2 2025	$21.3B	138
Q1 2025	$15.6B	133
Q4 2024	$15.8B	132
Q3 2024	$15.7B	146
Q2 2024	$14.5B	149
Q1 2024	$15.1B	160
Q4 2023	$13.8B	141
Q3 2023	$15.7B	148

Questions about Farallon Capital Management, L.l.c.'s portfolio

What stocks does Farallon Capital Management, L.l.c. own?

Farallon Capital Management, L.l.c.'s latest 13F, for Q2 2026 and filed Aug 14, 2026, lists 82 positions worth $16.9B. The largest are Revolution Medicines Inc (RVMD) at 15.0%, Electronic Arts Inc (EA) at 9.6%, Bridgebio Pharma Inc (BBIO) at 4.7%, Protagonist Therapeutics Inc (PTGX) at 4.6% and Exelixis Inc (EXEL) at 4.3%.

What did Farallon Capital Management, L.l.c. buy last quarter?

In Q2 2026, Farallon Capital Management, L.l.c. added Immunovant Inc (IMVT) (+275.5% shares), Johnson & Johnson (JNJ) (+175.7% shares) and Baidu Inc (BIDU) (+171.3% shares), compared with its Q1 2026 filing.

What did Farallon Capital Management, L.l.c. sell last quarter?

In Q2 2026, Farallon Capital Management, L.l.c. cut from its top 50 Charles Schwab Corp (the) (SCHW), cut from its top 50 Alphabet Inc (GOOG), cut from its top 50 Visa Inc (V), cut from its top 50 Disney Walt Co (DIS), cut from its top 50 Mastercard Incorporated (MA), Microsoft Corp (MSFT) (-52.5% shares), Aon PLC (AON) (-45.0% shares) and Merck & Co Inc (MRK) (-44.9% shares), compared with its Q1 2026 filing.

How has Farallon Capital Management, L.l.c.'s portfolio performed?

A portfolio copying Farallon Capital Management, L.l.c.'s 20 largest 13F holdings each quarter, from the day each filing was public, returned +17.1% a year over the last 3 years, against +19.0% for the S&P 500. Over 1 year: +30.6% against +14.9%. Over 5 years: +9.3% a year against +10.4%.

When is Farallon Capital Management, L.l.c.'s next 13F filing due?

13F filings are due 45 days after each quarter ends. Farallon Capital Management, L.l.c.'s filing for the quarter ending Sep 30, 2026 is due by Nov 14, 2026; this page updates the day after it is published.

How much money does Farallon Capital Management, L.l.c. manage?

Farallon Capital Management, L.l.c. reported $52.1B of regulatory assets under management on its latest SEC Form ADV. Its 13F, which covers only US-listed stocks and options, totals $16.9B.